Pfizer mRNA Vaccine Fades--No Protection Against Hospitalization Even Boosters Fall Short
Editor's Note: RISK-BENEFIT ANALYSIS . . . Injecting this poisonous crap into yourself is INSANE! The risks are devastating, the benefits don't exist!
Are the COVID-19 mRNA vaccines durability improving? No, they are not, and in fact, even if an individual followed public health instructions, getting three doses of the primary series to bolster protection with a mutating virus and a vaccine truly lacking in durability such as the Pfizer BNT162b2 product consumers are afforded absolutely no protection against hospitalization unless they get annual boosters. This is the clear message taken from the latest research led by researchers at Kaiser Permanente, Department of Research & Evaluation, Pasadena and other locations.
The team of physicians and epidemiologists pondered whether administration of the Pfizer BNT162b2 XBB vaccine offers additional protection against COVID-19 hospital admissions and ambulatory visits for US adults compared with not receiving a BNT162b2 XBB vaccine of any kind and whether older versions of the COVID-19 vaccine still provide any protection compared with being unvaccinated. Executing a case-control study targeting 2854 cases and 15, 345 controls, the Pfizer BNT162b2 XBB vaccine provided statistically significant additional protection against a range of COVID-19 outcomes during the early part of the 2023 to 2024 viral respiratory season according to the study outcomes. Older versions of COVID-19 vaccines offered no additional protection compared with being unvaccinated, including against COVID-19 hospital admissions, regardless of the number or type of prior doses received. Sara Y. Tartof, PhD, MPH and colleagues report their study outcomes support the current recommendations of the Centers for Disease Control and Prevention (CDC) for annual updates. Put another way, the COVID-19 mRNA vaccine durability continues to be a challenge, with waning effectiveness, necessitating the recommendation of an annual booster for any protection of hospitalization whatsoever. What is not contemplated are the potential long-term consequences of repeated mRNA boosters, year after year. This impact has not been studied.